Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.

[1]  L. Vassilev,et al.  Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy , 2013, Proceedings of the National Academy of Sciences.

[2]  Brian J. Smith,et al.  Structure-guided design of a selective BCL-X(L) inhibitor. , 2013, Nature chemical biology.

[3]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[4]  Victoria Del Gaizo Moore,et al.  BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. , 2013, Cancer letters.

[5]  Amy E Keating,et al.  Peptide ligands for pro-survival protein Bfl-1 from computationally guided library screening. , 2013, ACS chemical biology.

[6]  L. Walensky,et al.  Direct activation of full-length proapoptotic BAK , 2013, Proceedings of the National Academy of Sciences.

[7]  Amy E Keating,et al.  Predictive Bcl-2 family binding models rooted in experiment or structure. , 2012, Journal of molecular biology.

[8]  A. J. Link,et al.  A comparison of two strategies for affinity maturation of a BH3 peptide toward pro-survival Bcl-2 proteins. , 2012, ACS synthetic biology.

[9]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[10]  A. Strasser,et al.  Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases , 2011, The EMBO journal.

[11]  Chengyu Liang,et al.  Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX , 2011, Cell Research.

[12]  Erinna F. Lee,et al.  Mutation to Bax beyond the BH3 Domain Disrupts Interactions with Pro-survival Proteins and Promotes Apoptosis* , 2011, The Journal of Biological Chemistry.

[13]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[14]  A. Keating,et al.  Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. , 2010, Journal of molecular biology.

[15]  Derek W. Yecies,et al.  MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts , 2009, The Journal of cell biology.

[16]  Erinna F. Lee,et al.  High-resolution structural characterization of a helical alpha/beta-peptide foldamer bound to the anti-apoptotic protein Bcl-xL. , 2009, Angewandte Chemie.

[17]  C. Reynolds,et al.  Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.

[18]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[19]  S. Gellman,et al.  Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein–protein recognition: Application to the Bim BH3 domain , 2008, Protein science : a publication of the Protein Society.

[20]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[21]  D. Green,et al.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.

[22]  Erinna F. Lee,et al.  A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation , 2008, The Journal of cell biology.

[23]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[24]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[25]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[26]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[27]  K Dane Wittrup,et al.  Isolating and engineering human antibodies using yeast surface display , 2006, Nature Protocols.

[28]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[29]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[30]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[31]  S. Richardson,et al.  Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands* , 2005, Journal of Biological Chemistry.

[32]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[33]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[34]  S. Korsmeyer,et al.  Antiapoptotic BCL-2 is required for maintenance of a model leukemia. , 2004, Cancer cell.

[35]  A. Petros,et al.  Structural biology of the Bcl-2 family of proteins. , 2004, Biochimica et biophysica acta.

[36]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[37]  Ziwei Huang,et al.  The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. , 2002, Chemistry & biology.

[38]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[39]  A. Strasser,et al.  BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death , 2000, Cell.

[40]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[41]  Eric T. Boder,et al.  Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.

[42]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[43]  A. Petros,et al.  Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies , 2000, Protein science : a publication of the Protein Society.

[44]  C. Raymond,et al.  General method for plasmid construction using homologous recombination. , 1999, BioTechniques.